Company News

  • 21 January 2019

    Lilly reports negative results from cancer drug trial

    Eli Lilly and Company has reported negative results from the Announce trial, a Phase lll study of Lartruvo (olaratumab) in combination with doxorubicin to treat patients with advanced or metastatic...

  • 18 January 2019

    Aerpio completes dosing in TIME-2b study of AKB-9778

    Aerpio Pharmaceuticals has completed patient dosing in the Phase II TIME-2b clinical trial evaluating the efficacy and safety of AKB-9778 for the treatment of patients with moderate to severe non-proliferative...

Go Top